RBC Capital: European Medtech Firms Show Minimal Middle East and Energy Risk Exposure 
Microsoft's $10 Billion Japan Investment: AI Infrastructure and Data Sovereignty Push 
OpenAI Executive Shake-Up Ahead of Anticipated 2026 IPO 
Paramount Skydance Secures $24B from Gulf Sovereign Wealth Funds for Warner Bros. Discovery Takeover 
Microsoft Eyes $7B Texas Energy Deal to Power AI Data Centers 
TSMC Japan's Second Fab to Produce 3nm Chips by 2028 
Tesla Q1 2026 Deliveries Miss Estimates as AI Strategy Takes Center Stage 
SoftwareONE Posts 22.5% Revenue Surge in 2025 on Crayon Acquisition 
CTOC Adds 3,000 Doctors, 500 Hospitals Ahead of Liquidity Push 
Apple's Foldable iPhone Faces Engineering Setbacks, Mass Production Timeline at Risk 
UAE's Largest Natural Gas Facility Suspended After Attack-Triggered Fire 
Britain Courts Anthropic Amid US Defense Department Dispute 
Elon Musk Ties SpaceX IPO Access to Mandatory Grok AI Subscriptions 
Ukrainian Drones and the #MadeByHousewives Movement: Kyiv Fires Back at Rheinmetall CEO 
SpaceX Eyes Historic IPO at $1.75 Trillion Valuation 
MATCH Act Targets ASML and Chinese Chipmakers in New U.S. Export Crackdown 
Trump Administration Plans 100% Tariffs on Pharmaceutical Imports 
NEW YORK, Jan. 19, 2017 -- Safirstein Metcalf LLP announces that a class action lawsuit has been filed against Ophthotech Corporation ("Ophthotech" or the "Company") (NASDAQ:OPHT) and certain of its officers, and is on behalf of a class consisting of all persons or entities who purchased Ophthotech securities between May 11, 2015 and December 12, 2016, inclusive (the "Class Period").
If you purchased Ophthotech securities during the class period, and would like more information about getting involved in the Ophthotech Shareholder Class Action, please contact Sheila Feerick at 1-800-221-0015, or email [email protected]
If you wish to serve as lead plaintiff, you must move the Court no later than March 13, 2017. A lead plaintiff is a representative party acting on behalf of other class members in directing the litigation. Any member of the putative class may move the Court to serve as lead plaintiff through counsel of their choice, or may choose to do nothing and remain an absent class member.
This class action seeks to recover damages against Defendants for alleged violations of the federal securities laws under the Securities Exchange Act of 1934 (the "Exchange Act").
The Complaint alleges that throughout the Class Period, Defendants made overtly positive representations regarding its treatment Fovista's effectiveness and potential when used in combination with Lucentis, a commercially available anti-vascular endothelial growth factor agent. Ophthotech made these statements despite its apparent awareness that the phase 3 clinical trial of Fovista would not meet its primary endpoint of change in best corrected visual acuity from baseline at 12 months over Lucentis alone. The complaint further alleges that these statements caused Ophthotech stock to trade at artificially inflated prices.
On December 12, 2016, Ophthotech released its disappointing results for two phase 3 clinical trials that were testing its experimental compound Fovista combined with the Lucentis drug. Following this news, Ophthotech stock dropped close to 86% to $5.29 per share.
About Safirstein Metcalf LLP
Safirstein Metcalf LLP focuses its practice on shareholder rights. The law firm also practices in the areas of antitrust and consumer protection. All of the Firm’s legal endeavors are rooted in its core mission: provide investor and consumer protection.
Attorney advertising. Prior results do not guarantee a similar outcome.
Safirstein Metcalf LLP Peter Safirstein, Esq. 1250 Broadway 27th Floor New York, NY 10001 1-800-221-0015
